Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
about
Initial genome sequencing and analysis of multiple myelomaNovel agents for advanced pancreatic cancerExploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Targeting the RAS oncogene.Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsA new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsA mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaPhase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.MEK and the inhibitors: from bench to bedside.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsAS-703026 Inhibits LPS-Induced TNFα Production through MEK/ERK Dependent and Independent Mechanisms.Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaMEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsA clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.MEK inhibitors: a patent review 2008 - 2010.Understanding the molecular biology of myeloma and its therapeutic implications.MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.Emerging pathways as individualized therapeutic target of multiple myeloma.Prospects for MEK inhibitors for treating cancer.Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic TargetingImmunological dysregulation in multiple myeloma microenvironment.The biology and clinical development of MEK inhibitors for cancer.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonMethods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1.IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.Signaling Pathways and Emerging Therapies in Multiple Myeloma.Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles.Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
P2860
Q24629117-C3C76377-C407-49C7-8774-3A63A7B77872Q26787087-0E2C4704-C107-4E03-B616-8D0FF775440CQ27001584-2E9E1D3D-BFAD-4569-9DAA-3752B292B430Q27687198-E49D244F-B653-4FF9-85BC-C88D4C8A7D83Q28540339-97194C62-8516-4AAB-9829-8F8307E79ABCQ28541630-E06D3F6D-3B11-496C-B26D-152DBB929249Q30498959-4696EDCA-7A30-4BF6-B20C-6BFD288FB863Q33426534-655DAA63-BE42-4278-8072-09886D36DA2BQ33439312-56185C57-B9F1-4995-98FE-6B180A91CF45Q34036341-3ADFF1AF-A6A7-4C9B-BCEE-84BD6B42D491Q34307356-736E9176-B439-4DAF-A25A-E13B8CE31AF6Q35212644-A775848E-F2BD-4934-8385-A8E9DD76929CQ35779438-27977E4D-05C8-499A-A915-C99AA1EF50ECQ36086845-D4D1266E-8D0C-4707-BF12-82132A03FCF6Q36206430-0579DC4D-CDB2-4E2A-B2B0-55CA66FEA75FQ36328021-542F3945-14E8-408C-8BC8-8B2A7AB9B5FCQ36436089-8D998045-7BA1-435D-963B-10A466D0D89EQ37017342-71A29CAD-BEF6-4C6E-8533-405E3EF8B628Q37097110-A67F84DD-FE75-42E4-9454-EB587A29FC7BQ37132866-58C8B7C2-06C6-4C0D-9C07-BBAC07D28BD6Q37301884-D1B32B3D-DD2A-46B3-93FC-DA1582193930Q37697253-03E3A59C-4A7F-4B22-9AE0-2D187B3140ABQ37736641-26DF6238-BA30-4508-8FDD-918AD66759F3Q37872791-F90441EA-8116-4501-A265-65EC541391BCQ38065305-7C68D79A-6458-4C0F-BE1C-076EFDBE9200Q38092584-6441EA23-E6A7-4988-872C-C1D919C94608Q38112176-E0E5DA6B-F16F-4F8D-B2E6-88C53BEEB391Q38193520-81C8357A-F85D-46C4-B23B-F6BD64D28DFCQ38227885-102B84E5-CC73-479F-9101-C2AC196E1502Q38228353-4A5BEDC4-86FB-432A-99C9-42E367026DF1Q38270129-87D62FB8-E9B4-4DB9-8293-5239539D4F83Q38478630-09755AC7-D2BA-49F4-8863-08A18B0919E8Q38709385-FF43690A-379D-4BF1-B5E7-4933143BE69FQ38733973-EEF9D83E-C96D-4A1F-9DFF-0A1FE9D8DE79Q38734780-C342F0BD-191C-4EAC-A002-A8375D1C25C0Q38748203-0DCDCF20-23B4-4EF3-8EE7-D84B23F5DAA8Q38753307-FDEC731F-F393-41CF-8B0A-36CA7125040AQ38821763-553706E4-F875-4D6B-8235-40C078455F5AQ39264005-E772A13D-3538-4290-B174-0F0BDE71F2DBQ39277209-5CEA7F08-28AA-49C9-A6A8-490989037806
P2860
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@ast
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@en
type
label
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@ast
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@en
prefLabel
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@ast
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@en
P2093
P2860
P1476
Blockade of the MEK/ERK signal ...... activity in vitro and in vivo
@en
P2093
Andreas Goutopoulos
Dharminder Chauhan
Janet Ogden
Kenneth C Anderson
Klaus Podar
Luca Rastelli
Mariateresa Fulciniti
Mathew J Rumizen
Nikhil C Munshi
P2860
P304
P356
10.1111/J.1365-2141.2010.08127.X
P407
P50
P577
2010-03-12T00:00:00Z